Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway
2016-05-06 | journal article; research paper
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway
Korkmaz-Icöz, S.; Al Said, S.; Radovits, T.; Li, S.; Brune, M.; Hegedűs, P. & Atmanli, A. et al. (2016)
Cardiovascular Diabetology, 15(1) pp. 75. DOI: https://doi.org/10.1186/s12933-016-0383-8
Documents & Media
Details
- Authors
- Korkmaz-Icöz, Sevil; Al Said, Samer; Radovits, Tamás; Li, Shiliang; Brune, Maik; Hegedűs, Péter; Atmanli, Ayhan; Ruppert, Mihály; Brlecic, Paige; Lehmann, Lorenz Heyne; Lahrmann, Bernd; Grabe, Niels ; Yoshikawa, Yutaka; Yasui, Hiroyuki; Most, Patrick; Karck, Matthias; Szabó, Gábor
- Abstract
- Type-2 diabetics have an increased risk of cardiomyopathy, and heart failure is a major cause of death among these patients. Growing evidence indicates that proinflammatory cytokines may induce the development of insulin resistance, and that anti-inflammatory medications may reverse this process. We investigated the effects of the oral administration of zinc and acetylsalicylic acid, in the form of bis(aspirinato)zinc(II)-complex Zn(ASA)2, on different aspects of cardiac damage in Zucker diabetic fatty (ZDF) rats, an experimental model of type-2 diabetic cardiomyopathy.
- Issue Date
- 6-May-2016
- Journal
- Cardiovascular Diabetology
- ISSN
- 1475-2840
- eISSN
- 1475-2840
- Language
- English
